FHC08511
Human
Mouse
IgG1
Monoclonal
FITC
von Willebrand antigen II, von Willebrand factor, F8VWF, vWF, VWF
0.5 mg/ml
Please contact with the lab for this information.
FCM
Liquid
0.01M PBS, pH 7.4, 0.2% BSA, 0.05% Proclin 300.
Store at 4°C for 12 months. Protect from light. Do not freeze.
NMC-4
Is COVID-19 Coagulopathy a Thrombotic Microangiopathy? A Prospective, Observational Study., PMID:40508203
Anti-β2GPI/β2GPI complex promotes thrombosis by activating the P2Y2/MAPKs pathway to increase human neutrophil peptides., PMID:40403008
Perioperative management of transcatheter aortic valve implantation in acquired von Willebrand syndrome secondary to monoclonal gammopathy: a case report., PMID:40395684
Immune Thrombotic Thrombocytopenic Purpura: A Review., PMID:40388146
Thrombospondin-1 inhibits alternative complement pathway activation in antineutrophil cytoplasmic antibody-associated vasculitis., PMID:40338657
Topographic relationship between glial cells and neovessels of the epiretinal membrane in proliferative diabetic retinopathy depends on the phase of angiogenesis., PMID:40336843
Polyunsaturated Fatty Acids Improved Long Term Prognosis by Reducing Oxidative Stress, Inflammation, and Endothelial Dysfunction in Acute Coronary Syndromes., PMID:40278275
Optimization of nanobody caplacizumab via computational design., PMID:40226960
A retrospective study on the correlation between antibody levels and endothelial function in SLE patients: An analysis based on ultrasound and serum biomarkers., PMID:40073698
Early administration of caplacizumab combined with plasma exchange for thrombotic microangiopathy due to malignant hypertension: a case report., PMID:40029564
Preventative and therapeutic effects of a novel humanized anti-glycoprotein Ibα fragment of antigen-binding region in a murine model of thrombotic thrombocytopenic purpura., PMID:39956431
Coagulation Profile of Convalescent Plasma Donors and Recipients., PMID:39886886
Efficient and Reproducible Differentiation Protocol for Pluripotent Stem Cells into Functional Endothelial Cells: Unveiling the Path to Vascular Regeneration., PMID:39837100
The epitope of the antibody used in the REAADS VWF activity assay is quaternary., PMID:39825354
By activating endothelium histone H4 mediates oleic acid-induced acute respiratory distress syndrome., PMID:39757148
Jararaca GPIb-binding protein causes thrombocytopenia during Bothrops jararaca envenomation., PMID:39738271
Interpreting high levels of unfolded Von Willebrand Factor in patients with the antiphospholipid syndrome., PMID:39726607
Ex vivo evaluation of the effect of plasma-derived factor VIII/von Willebrand factor in patients with severe hemophilia A on emicizumab prophylaxis., PMID:39708197
Mechanistic insight into multiple antibody binding to ADAMTS13 in immune thrombotic thrombocytopenic purpura., PMID:39624585
A fully humanized von Willebrand disease type 1 mouse model as unique platform to investigate novel therapeutic options., PMID:39605214
The role of protein kinase C and the glycoprotein Ibα cytoplasmic tail in anti-glycoprotein Ibα antibody-induced platelet apoptosis and thrombocytopenia., PMID:39541612
Increased thrombin generation in kidney transplant recipients with donor-specific antibodies directed against human leukocyte antigens., PMID:39524447
Current and emerging therapies as potential treatment for people with von Willebrand disease., PMID:39530919
[100 years thrombotic thrombocytopenic purpura (TTP) - lessons learned?]., PMID:39504978
Laboratory Testing for ADAMTS13 for Thrombotic Thrombocytopenia Purpura and Beyond., PMID:39467573
Misleading antigenic von Willebrand factor levels in acquired von Willebrand syndrome secondary to monoclonal gammopathy of undetermined significance., PMID:39446195
Bleeding management in type 3 von Willebrand disease with anti-von Willebrand factor inhibitor: A literature review and case report., PMID:39415910
Refining the standard of care in immune thrombotic thrombocytopenic purpura., PMID:39356816
Risk stratification analysis of recurrent myocardial infarction in Indian population using inflammatory, lipid, thrombotic and extracellular matrix remodeling markers., PMID:39351476
Autoantibodies to ADAMTS13 in human immunodeficiency virus-associated thrombotic thrombocytopenic purpura., PMID:39293938
[Platelet-specific Rictor knockout inhibits platelet production and activation and reduces thrombosis in mice]., PMID:39276057
Improved prevention of bleeding episodes with emicizumab in 3 patients with concomitant hemophilia A and von Willebrand disease., PMID:39248053
Legionella Pneumophila Presenting as a Rare Cause of Acute Thrombocytopenia: A Case Report and Review of Literature., PMID:39247236
Converging pathways: acquired von Willebrand disease in systemic lupus erythematosus with antiphospholipid antibodies presenting with persistent menstrual bleeding., PMID:39231562
A rare case of acquired von Willebrand syndrome type 2B: diagnosis, treatment, and underlying pathophysiology., PMID:39228434
A comparative study of anti-ADAMTS-13 antibody dynamics in immune-mediated thrombotic thrombocytopenic purpura., PMID:39221447
The Phenomenon of Thrombotic Microangiopathy in Cancer Patients., PMID:39201740
Platelet-Type von Willebrand Disease: Complex Pathophysiology and Insights on Novel Therapeutic and Diagnostic Strategies., PMID:39191406
Factor VIII stimulants and other novel therapies for the treatment of von Willebrand disease: what's new on the horizon?, PMID:39155445
Animal models for thrombotic thrombocytopenic purpura: a narrative review., PMID:39148951
Novel GPIb-independent platelet aggregation induced by botrocetin: implications for diagnosis and antithrombotic therapy., PMID:39147240
Increased vascular deposition of oxidized LDL in untreated juvenile dermatomyositis., PMID:39118148
Percutaneous Left Atrial Appendage Closure in a Patient With Acquired Von Willebrand Disease and Atrial Fibrillation., PMID:39105017
Prevalence and characterization of anti-VWF antibodies in a population of patients with type 3 VWD., PMID:39088757
The impact of von Willebrand factor on fibrin formation and structure unveiled with type 3 von Willebrand disease plasma., PMID:38973517
Caplacizumab in pediatric immune thrombotic thrombocytopenic purpura: the UK TTP Registry experience., PMID:38968147
[Advances in the treatment of thrombotic thrombocytopenic purpura]., PMID:38960658
[Novel treatment strategies for acquired hemophilia A]., PMID:38960657
Emicizumab in Type 3 von Willebrand Disease: Report of a Case with an Alloantibody and Literature Review., PMID:38936417
Retrospectively diagnosed autoimmune VWF deficiency in a patient with repeated hemorrhagic events after two common colds., PMID:38761278
Order: order@antibodysystem.com
Mail: support@antibodysystem.com
For research use only. Not for human or drug use.
Find out more about placing an order here
